Upcoming events

Reagan Jarvis, our CEO, is presenting 'Systematic Isolation & Characterization of Clinical TCR Candidates' at the TCR-Based Therapies for Solid Tumours, where he discusses native and optimized TCR frameworks, TCR cross-reactivity including insights and practical benchmarks and preventing TCR allo-reactivity.

Reach out to us if you would like to meet.

We are delighted to be one of the sponsors of this year's 2023 Cell & Gene Meeting on the Med, with Mark Farmery, our CDO and Brian McGee, our CBO presenting Anocca, our technology platforms and our pipeline of novel T-cell therapies.

Reach out to us if you would like to meet.

Reagan Jarvis, our CEO, is presenting 'Showcasing Individualised Neoantigen Discovery Platform' at the TCR-Based Therapies for Solid Tumours, where he talks about understanding HLA-restricted neoantigen target complexity with cell-based assays, validating neoantigen targets with T-cell Receptor reagents derived by rapid
multiplex discovery and considering TCR potency and safety trade-off for HLA-restricted neoantigens.

Reach out to us if you would like to meet.